GlassScriptPhysician profile
Kellie A Goldsborough
NPI 1649226614
$7,454.65
in general payments reported to CMS, 2019-2025
33 companies · $709 in 2025
The $709 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,402 · 2020: $554 · 2021: $1,087 · 2022: $1,430 · 2023: $1,176 · 2024: $1,096 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,748 · Consulting Fee: $175 · Education: $58.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,748.04 |
| Consulting Fee | $175.00 |
| Education | $58.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $879.82 | 2019-2025 | Tavneos, Uplizna, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $716.02 | 2019-2025 | Farxiga, Lokelma |
| Alexion Pharmaceuticals, INC. | $644.52 | 2019-2025 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $556.30 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $556.23 | 2019-2025 | Veltassa |
| Horizon Therapeutics Plc | $508.29 | 2020-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $446.15 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $394.71 | 2020-2024 | Terlivaz, Acthar |
| Aurinia Pharma U.S., INC. | $378.51 | 2021-2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $331.42 | 2019-2023 | Rayaldee |
| Mallinckrodt Enterprises LLC | $311.85 | 2019 | |
| Glaxosmithkline, LLC. | $248.22 | 2021-2025 | Benlysta |
| Travere Therapeutics, INC. | $225.41 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $184.10 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $170.57 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $132.06 | 2022-2025 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $109.62 | 2021-2023 | Korsuva, Velphoro |
| Boston Scientific Corporation | $108.42 | 2019 | |
| Akebia Therapeutics INC | $98.02 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.63 | 2022-2024 | Jardiance |
| Daiichi Sankyo INC. | $67.46 | 2021-2022 | |
| Novo Nordisk INC | $46.44 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Alnylam Pharmaceuticals INC. | $40.83 | 2023-2025 | Givlaari, Onpattro |
| Kyowa Kirin, INC. | $40.55 | 2023-2024 | Crysvita |
| Ardelyx, INC. | $40.26 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $30.62 | 2019 | |
| Shire North American Group INC | $20.49 | 2019 | |
| Scpharmaceuticals INC. | $20.43 | 2025 | |
| Lilly USA, LLC | $16.96 | 2024 | Jardiance |
| Recordati_rare_diseases_inc. | $16.88 | 2025 | Cystadrops |
| Ultragenyx Pharmaceutical INC. | $15.75 | 2021 | |
| Shield Therapeutics INC | $15.16 | 2024 | |
| Janssen Pharmaceuticals, INC | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Goldsborough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.